Agilent Technologies, Inc. - 10-Q Summary (Q2 FY2026)
Business Context and Reporting Period
This filing covers the quarterly period ended April 30, 2026 (Fiscal Q2 2026). Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets, providing instruments, software, services, and consumables. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Net Revenue | $1,835 | $1,668 | $3,633 | $3,349 |
| Net Income | $339 | $215 | $644 | $533 |
| Diluted EPS | $1.20 | $0.75 | $2.27 | $1.86 |
| Operating Income | $399 | $300 | $752 | $676 |
| Operating Margin | 21.7% | 18.0% | 20.7% | 20.2% |
| Free Cash Flow (Proxy) | $376 (6mo) | $441 (6mo) | $376 (6mo) | $441 (6mo) |
| Cash & Equivalents | $1,807 | $1,789 (Oct 2025) | $1,807 | $1,789 (Oct 2025) |
| Total Debt | $3,355 | $3,354 (Oct 2025) | $3,355 | $3,354 (Oct 2025) |
Note: Free Cash Flow calculated as Net Cash from Operating Activities ($545M) less Capital Expenditures ($169M) for the six months ended April 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 10% year-over-year (YoY) for Q2 and 8% for the six-month period. Growth was driven by all three segments and all geographic regions.
- Profitability Expansion: Operating margin expanded 370 basis points to 21.7% in Q2, driven by higher sales volume, targeted price increases, and lower restructuring expenses. Net income surged 58% YoY in Q2.
- Segment Performance:
- Life Sciences & Diagnostics: Revenue up 12% (Q2) and 8% (6mo), led by pharmaceutical and diagnostics markets.
- Agilent CrossLab: Revenue up 6% (Q2) and 8% (6mo), with strong growth in services and consumables.
- Applied Markets: Revenue up 14% (Q2) and 10% (6mo), driven by chemical/advanced materials and environmental/forensics markets.
- Restructuring Costs: Restructuring expenses decreased significantly to $8 million in Q2 2026 compared to $56 million in Q2 2025, contributing to margin improvement.
Guidance, Outlook, and Risks
- Acquisition: Agilent entered a definitive agreement on March 6, 2026, to acquire Biocare for approximately $950 million in cash. Closing is expected in Q3 or by the end of FY2026.
- Capital Allocation: The company repurchased 1.6 million shares for $217 million in the first six months of FY2026. Approximately $1.732 billion remains available under the 2024 repurchase program. A quarterly dividend of $0.255 per share was declared.
- Geopolitical & Trade Risks:
- Tariffs: The U.S. Supreme Court invalidated certain IEEPA tariffs in February 2026. Agilent has submitted refund claims, but timing is uncertain. No refund receivable has been recorded as of April 30, 2026.
- Geopolitics: Middle East conflicts have increased economic uncertainty but did not materially impact Q2 results due to mitigation strategies.
- Outlook: Management remains optimistic about long-term end market health, noting that customer capital spending is normalizing after a period of constraint, except for U.S. federal government-funded customers.
Investor Verification Checklist
- Biocare Acquisition: Verify the closing timeline and integration costs for the $950 million Biocare acquisition.
- Tariff Refunds: Monitor the status of IEEPA tariff refund claims and potential impact on future cash flows.
- Government Funding: Assess the impact of U.S. federal funding constraints on the Academia and Government end market, which saw revenue declines.
- Capital Expenditures: Confirm the $450 million full-year CapEx guidance, specifically regarding the expansion of advanced therapeutics manufacturing in Colorado.
- Restructuring Completion: Track the completion of the FY25 restructuring plan and the realization of the estimated $90-$95 million in annual cost savings.